Examination of IFNAR1 expression on CD103+ DCs from the treatment groups in our colitis model revealed that there was a reduction in receptor expression in mice pretreated with La-IFN-β in all of the intestinal tissues we examined, with the most significant reduction occurring in the PPs. The gene discussed is IFNAR1; the disease is colitis.